Skip to main content
. Author manuscript; available in PMC: 2014 Jul 15.
Published in final edited form as: Int J Cancer. 2013 Feb 12;133(2):373–382. doi: 10.1002/ijc.28026

Table 1.

Suppressive activity of CD4+CD25high Treg samples

Samples CD4+CD25high Treg suppressive activity
HD1 44.3%
HD2 44.1%
HD3 56.1%
PCa 1 44.0%
PCa 2 55.8%
PCa 3 51.7%

Results are expressed as % of suppressive activity of CD4+CD25high Treg against the proliferation of CD4+CD25 effector T-cell.

HD = healthy donor; PCa = metastatic prostate cancer patient.